Back Menu
id опорной категории = 2
id текущей категории = 1
id родительской категории = 1

HSCI Begins Trials of a New Coronavirus Vaccine

Betuvaks LLC, a subsidiary of Human Stem Cells Institute (HSCI), has entered into an agreement with the contract research company KEG Bio LLC and has begun preclinical trials of a vaccine candidate for the prevention of the new coronavirus infection.

Clinical trials for the SARS-CoV-2 vaccine are scheduled to begin in Q1 2021.

HSCI has founded Betuvaks to develop and introduce a coronavirus vaccine.

In the summer of 2020, HSCI conducted preliminary trials of 9 candidate drugs in animal models. As a result, one vaccine candidate was selected for preclinical and clinical trials, further development and state registration.

CoviVax, an original immunobiological drug developed by Betuvaks, consists of nanoparticles that mimic the SARS-CoV-2 virus but are actually not a virus and are incapable of infecting humans or mammals.

Preclinical and clinical trials of the vaccine should provide evidence that the drug induces the development of specific immunity to the new coronavirus infection.

Artur Isaev, Chairman of HSCI’s Board of Directors, says, «Coronavirus prevention and vaccination will be an important issue not only during 2021, but much longer. The matters on the agenda already include the ability of vaccines not only to stimulate the production of antibodies, but also to protect against the virus, the long-term effects and safety, the duration of immunity after vaccination, and re-vaccination. However, the approaches of many coronavirus vaccine developers are based on technologies they had in development and on hand, and which they developed before the epidemic, and they often do not consider the need for re-vaccination and the potential distant effects of vaccination upon re-exposure to the virus. We previously decided that HSCI would use its own experience and expertise in innovative development, build a team of developers, and invest some of its own money in the development of a coronavirus vaccine with the possibility of using it for re-vaccinations.»